Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Frontiers in Cardiovascular Medicine

Traditional Chinese medicine and RhoA/ROCK signaling in myocardial ischemia/reperfusion injury: a narrative review of preclinical evidence

  1. 1Heilongjiang University of Chinese Medicine
  2. 2Zhejiang Chinese Medical University
  3. 3The Fourth Affiliated Hospital of Harbin Medical University

Abstract

Ischemic heart disease is one of the major diseases that affect human health, and it has high morbidity and mortality rates globally. The primary clinical strategy for its treatment is prompt restoration of blood supply to the ischemic myocardium. Nevertheless, reperfusion of blood flow can exacerbate myocardial damage, leading to myocardial ischemia/reperfusion injury (MIRI). RhoA/rho-associated protein kinase (ROCK) signaling plays a pivotal role in cardiovascular diseases and is a candidate therapeutic target in MIRI. However, its role is bidirectional: the intensity and duration of activation, the phase of ischemia and reperfusion, the cell type in which the signal arises, and the downstream effector engaged together determine whether RhoA signaling injures or protects the myocardium. Protection is carried by branches acting through protein kinase D, PINK1/Parkin, and myocardin-related transcription factor A so that intervention is directed at correcting pathological overactivation rather than blocking the pathway. Traditional Chinese medicine (TCM) has long been used in ischemic heart disease and is extensively studied as an intervention against MIRI. In addition, active ingredients of Chinese medicinal herbs, TCM compound prescriptions, and electroacupuncture alleviate oxidative stress, maintain calcium ion homeostasis and mitochondrial function, and suppress inflammatory responses and apoptosis, and these effects are accompanied by suppression of excessive RhoA/ROCK activation. However, most of the available studies report only changes in RhoA or ROCK expression, and the evidence establishing RhoA as a necessary target of these interventions remains limited. The clinical trials completed for these interventions used coronary flow and exercise capacity as endpoints without measuring the pathway in patients, and their translation remains to be established. This narrative review summarizes the research on TCM modulation of the RhoA signaling pathway in MIRI and appraises the current state of its clinical translation.

Related

  1. Blocking MyD88 Signaling Pathway Protects Against Myocardial Ischemia Reperfusion by Inhibiting NOX/ROS Pathway and Enhancing eNOS Activity
    Bo Wang, Xia Huang, Lin Xie
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0General medicineCrossref
  2. Superior cervical sympathetic ganglionectomy protects against diabetic myocardial ischemia/reperfusion injury via α7nAChR/JAK2/STAT3 signaling pathway
    Jiahong Gao, Shaoling Wang, Lesi Chen +1
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Cardiovascular medicineCrossref
  3. Protective effects and underlying mechanisms of naringenin in myocardial ischemia/reperfusion injury: a systematic review and preclinical meta-analysis
    Zuoyun He, Na Xie, Xupeng Shao +10
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Pharmacology & toxicologyFrontiersCrossref
  4. Statement of Retraction: Baicalin regulates macrophages polarization and alleviates myocardial ischaemia/reperfusion injury via inhibiting JAK/STAT pathway.
    Pharmaceutical biologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCDOAJ
  5. Myocardial Ischemia-Reperfusion Injury: Molecular Mechanisms and Innovative Therapeutic Strategies
    Dong Zhang, Xiaoting Yang, Shengyu Gong +4
    Reviews in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
BibTeX
@article{mo2026traditional,
  title = {{Traditional Chinese medicine and RhoA/ROCK signaling in myocardial ischemia/reperfusion injury: a narrative review of preclinical evidence}},
  author = {Guo-Teng Mo and Shengwen Jiang and Tao Feng},
  journal = {Frontiers in Cardiovascular Medicine},
  year = {2026},
  month = nov,
  doi = {10.3389/fcvm.2026.1961798},
  url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1961798/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Traditional Chinese medicine and RhoA/ROCK signaling in myocardial ischemia/reperfusion injury: a narrative review of preclinical evidence
AU  - Guo-Teng Mo
AU  - Shengwen Jiang
AU  - Tao Feng
PY  - 2026
DA  - 2026/11/06
JO  - Frontiers in Cardiovascular Medicine
DO  - 10.3389/fcvm.2026.1961798
UR  - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1961798/full
AB  - Ischemic heart disease is one of the major diseases that affect human health, and it has high morbidity and mortality rates globally. The primary clinical strategy for its treatment is prompt restoration of blood supply to the ischemic myocardium. Nevertheless, reperfusion of blood flow can exacerbate myocardial damage, leading to myocardial ischemia/reperfusion injury (MIRI). RhoA/rho-associated protein kinase (ROCK) signaling plays a pivotal role in cardiovascular diseases and is a candidate therapeutic target in MIRI. However, its role is bidirectional: the intensity and duration of activation, the phase of ischemia and reperfusion, the cell type in which the signal arises, and the downstream effector engaged together determine whether RhoA signaling injures or protects the myocardium. Protection is carried by branches acting through protein kinase D, PINK1/Parkin, and myocardin-related transcription factor A so that intervention is directed at correcting pathological overactivation rather than blocking the pathway. Traditional Chinese medicine (TCM) has long been used in ischemic heart disease and is extensively studied as an intervention against MIRI. In addition, active ingredients of Chinese medicinal herbs, TCM compound prescriptions, and electroacupuncture alleviate oxidative stress, maintain calcium ion homeostasis and mitochondrial function, and suppress inflammatory responses and apoptosis, and these effects are accompanied by suppression of excessive RhoA/ROCK activation. However, most of the available studies report only changes in RhoA or ROCK expression, and the evidence establishing RhoA as a necessary target of these interventions remains limited. The clinical trials completed for these interventions used coronary flow and exercise capacity as endpoints without measuring the pathway in patients, and their translation remains to be established. This narrative review summarizes the research on TCM modulation of the RhoA signaling pathway in MIRI and appraises the current state of its clinical translation.
SN  - 2297-055X
ER  -